Actively Recruiting
Phase IV Study of Cosibelimab for Advanced Cutaneous Squamous Cell Carcinoma in Patients with Kidney Transplants or Blood Cancers
Led by Dana-Farber Cancer Institute · Updated on 2026-08-11
80
Participants Needed
2
Research Sites
104 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of cosibelimab, an anti-PD-L1 antibody, in special populations with advanced cutaneous squamous cell carcinoma CSCC. This Phase IV clinical trial focuses on patients who either have a history of kidney transplant or a co-diagnosis of hematologic malignancy. The study is conducted across multiple sites and supported by Checkpoint Therapeutics and Dana-Farber Cancer Institute. Participants are divided into two groups Group A includes kidney transplant recipients who will receive cosibelimab along with prednisone and either sirolimus or everolimus Group B includes patients with hematologic malignancies who will receive cosibelimab alone. Treatment cycles occur every 21 days for up to 17 cycles, followed by regular three-month follow-up visits and long-term monitoring. Cosibelimab is given as an intravenous infusion, while other drugs are taken daily according to standard care. During the study, participants undergo screening, baseline assessments, blood and urine tests, CT or PET scans, ECGs, tumor biopsies, and aspirations. Researchers will measure tumor response, adverse events, allograft rejection in kidney transplant recipients, progression-free survival, overall survival, and other outcomes up to about three years. Safety and efficacy data are collected throughout treatment and follow-up periods, with total participation lasting until study completion in 2032.
CONDITIONS
Brief Title
Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy
Research Team
A
Ann Silk, MD
A
Ann Silk, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here